Advertisement

Topics

PubMed Journals Articles About "Global Biosimilars Market Research Report Forecast 2017 2022" RSS

12:26 EDT 21st October 2018 | BioPortfolio

Global Biosimilars Market Research Report Forecast 2017 2022 PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest Global Biosimilars Market Research Report Forecast 2017 2022 articles that have been published worldwide.

More Information about "Global Biosimilars Market Research Report Forecast 2017 2022" on BioPortfolio

We have published hundreds of Global Biosimilars Market Research Report Forecast 2017 2022 news stories on BioPortfolio along with dozens of Global Biosimilars Market Research Report Forecast 2017 2022 Clinical Trials and PubMed Articles about Global Biosimilars Market Research Report Forecast 2017 2022 for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Global Biosimilars Market Research Report Forecast 2017 2022 Companies in our database. You can also find out about relevant Global Biosimilars Market Research Report Forecast 2017 2022 Drugs and Medications on this site too.

Showing "Global Biosimilars Market Research Report Forecast 2017 2022" PubMed Articles 1–25 of 40,000+

Vital Signs: Prevalence of Key Cardiovascular Disease Risk Factors for Million Hearts 2022 - United States, 2011-2016.

Despite decades-long reductions in cardiovascular disease (CVD) mortality, CVD mortality rates have recently plateaued and even increased in some subgroups, and the prevalence of CVD risk factors remains high. Million Hearts 2022, a 5-year initiative, was launched in 2017 to address this burden. This report establishes a baseline for the CVD risk factors targeted for reduction by the initiative during 2017-2021 and highlights recent changes over time.


Vital Signs: State-Level Variation in Nonfatal and Fatal Cardiovascular Events Targeted for Prevention by Million Hearts 2022.

Despite its preventability, cardiovascular disease remains a leading cause of morbidity, mortality, and health care costs in the United States. This study describes the burden, in 2016, of nonfatal and fatal cardiovascular events targeted for prevention by Million Hearts 2022, a national initiative working to prevent one million cardiovascular events during 2017-2021.

Belgian IBD research group (BIRD) position statement 2017 on the use of biosimilars in inflammatory bowel diseases (IBD).


The mathematics of market timing.

Market timing is an investment technique that tries to continuously switch investment into assets forecast to have better returns. What is the likelihood of having a successful market timing strategy? With an emphasis on modeling simplicity, I calculate the feasible set of market timing portfolios using index mutual fund data for perfectly timed (by hindsight) all or nothing quarterly switching between two asset classes, US stocks and bonds over the time period 1993-2017. The historical optimal timing path ...

The complexities of biosimilars and the regulatory approval process.

Created via the Biologics Price Competition and Innovation Act, the biosimilar class of drugs was conceived as an opportunity to introduce competition for commonly used biologics following loss of patent protection and market exclusivity, similar to the generic paradigm that has helped sustain access and innovation for more than 3 decades. The FDA approves a biosimilar after a manufacturer establishes that the product is highly similar to a previously approved originator biologic reference product without a...

Proceedings of the 2017 International Forum on Gonococcal Infections and Resistance (2017 IFGIR) in Shenzhen, China.

The 2017 International Forum on Gonococcal Infections and Resistance (2017 IFGIR) was held at Shenzhen, China from 17 to 19 September 2017. The key objectives were to gather experts in the field to review and analyze the epidemiological profiles of gonococcal infections and antimicrobial resistance (AMR) at global, regional and national levels; to share and discuss findings from ongoing and completed research studies; and to identify research needs to respond to the spread of gonococcal infections and AMR. ...

Opportunities and challenges in biosimilar uptake in oncology.

There are now 10 approved biosimilars in the United States, including 3 oncology drugs, and at least 16 others in late-stage development. The introduction of competition into the biologic space launches a new era in the treatment of cancer, possibly increasing access to the extremely costly biologics. The most important and influential stakeholders for biosimilar acceptance and usage are healthcare providers, such as pharmacists and physicians, as well as patients. Gaining their support requires extensive e...

Bibliometric analysis of global publications in medication adherence (1900-2017).

Medication non-adherence is a worldwide problem. The aim of this study was to assess the global research output, research trends and topics that shaped medication adherence research.

How similar is biosimilar? A comparison of Infliximab therapeutics in regard to charge variant profile and antigen binding affinity.

Biosimilars are increasing in economic importance. Just how similar a biosimilar needs to be to gain market approval is currently still decided on a per case basis. We try to shed light on one often cited critical quality attribute of monoclonal antibodies, namely charge heterogeneity. Using high resolution electrophoretic and chromatographic methods, we are able to separate and quantify the charge variant content of infliximab originator and three biosimilars. Additionally we quantified and compared the an...

Use of Biosimilars in Paediatric Inflammatory Bowel Disease: An Updated Position Statement of the Paediatric IBD Porto Group of ESPGHAN.

Biologic therapies have changed the outcome of both adult and paediatric patients with Inflammatory Bowel Disease (IBD). In September 2013, the first biosimilar of infliximab was introduced into the pharmaceutical market. In 2015, a first position paper on the use of biosimilars in paediatric IBD was published by the ESPGHAN IBD Porto group. Since then, more data have accumulated for both adults and children demonstrating biosimilars are an effective and safe alternative to the originator. In this updated p...

Biosimilars: Expert consensus of the Latin American Society of Psoriasis (SOLAPSO) in Argentina.

With the appearance of biological treatments, therapeutics has changed in many rheumatological, dermatological and oncological diseases. Due to the high cost of these biological medicaments and the expiration of patents, the pharmacological industry develops biosimilars, drugs that are a version (copy) of the substance of the original biological medicine, with the aim of facilitating access to these treatments. These biosimilars are prepared according to the specific requirements of regulatory bodies in ter...

The social issue in the BRICS Project.

BRICS, the acronym for Brazil, Russia, India, China and South Africa, is the first multilateral group created and run by non-western developed countries. The group aims to influence world geopolitics and market based on the right of developing and emerging countries to participate equitably in development. The social issue lies at the core of the group's justifications to achieve its goals. In this regard, this paper aims to analyze how the social issue has been addressed by BRICS. The methodology was based...

Analysis of global stock index data during crisis period via complex network approach.

Considerable research has been done on the complex stock market, however, there is very little systematic work on the impact of crisis on global stock markets. For filling in these gaps, we propose a complex network method, which analyzes the effects of the 2008 global financial crisis on global main stock index from 2005 to 2010. Firstly, we construct three weighted networks. The physics-derived technique of minimum spanning tree is utilized to investigate the networks of three stages. Regional clustering ...

Recent Advances in Drug Development and Regulatory Science in China.

As the second largest pharmaceutical market with a great potential for future growth, China has drawn much attention from the global pharmaceutical community. With an increasing government investment in biomedical research, the domestic biopharmaceutical (biotechnological) companies in China are turning their attention to the development of innovative medicines and targeting the global market. To introduce innovative products to Chinese patients sooner, to improve the efficiency of its review and approval p...

Global Emergency Medicine: A review of the literature from 2017.

The Global Emergency Medicine Literature Review (GEMLR) conducts an annual search of peer-reviewed and gray literature relevant to global emergency medicine (EM) to identify, review, and disseminate the most important new research in this field to a global audience of academics and clinical practitioners.

The Australian Sentinel Practices Research Network, 1 January to 31 March 2017.

The Australian Sentinel Practices Research Network was established in 1991 to provide a rapid, national, monitoring scheme for infectious diseases that can alert public health officials of epidemics before they arise. The network consists of general practitioners, throughout all 8 states and territories in Australia, who report presentations on a number of defined medical conditions each week. This report presents data from the 1st quarter of 2017 (1 January to 31 March) and includes the syndromic surveilla...

Biosimilar Knowledge Among Oncology/Hematology Team Members in Colorado, USA: An Educational Initiative and Follow-Up Survey.

No data exist regarding oncology/hematology team members' knowledge of and views on biosimilars in Colorado, USA. Published research has suggested that health professionals may have a poor understanding of many issues related to biosimilars.

Experience in the global forum of bioethics in research. Challenges for the ethical review in Chile.

The Global Forum on Bioethics in Research annually convenes a number of researchers, bioethicists and stakeholders with a shared interest in the ethics of conducting research in low and middle-income countries (LMIC). It provides a useful platform to discuss ethical issues that affect research practice in different scenarios, promoting ethically conducted research, global development for health research ethics and partnerships between the global north and south. As participant of the last three meetings, in...

Biosimilars in oncology and inflammatory diseases: current and future considerations for clinicians in Latin America.

Biological therapies have revolutionized the treatment of several cancers and systemic immune-mediated inflammatory conditions. Expiry of patents protecting a number of biologics has provided the opportunity to commercialize highly similar versions, known as biosimilars. Biosimilars are approved by regulatory agencies via an independent pathway that requires extensive head-to-head comparison with the originator product. Biosimilars have the potential to provide savings to healthcare systems and expand patie...

Is the microbiome influencing patient care in lower urinary tract dysfunction? Report from the ICI-RS 2017.

This report sets out to consider the role of the microbiome within the bladder to provide clinicians with knowledge on this specific area of research and recommend potential topics for further studies.

Practical Guidance on Biosimilars, With a Focus on Latin America: What Do Rheumatologists Need to Know?

Availability of biologic disease-modifying antirheumatic drugs (bDMARDs) has improved clinical outcomes in rheumatoid arthritis, but it also increased the cost of treatment. Biosimilars, the regulated copies of biologic products, have a potential to reduce health care costs and expand access to treatment. However, because of a complex development process, biosimilars can be considered only those noninnovator biologics with satisfactory supporting evidence (ranging from structural to clinical), as outlined i...

Presidential address 2017 William Harkness FRCS October 10th 2017 Denver, Co USA: 2017-annus mirabilis, a global view of neurosurgery for children.

The following presidential address was delivered at the 45th Annual Meeting of the ISPN held in Denver, CO, USA in October 2017.

Substandard and falsified medical products are a global public health threat. A pilot survey of awareness among physicians in Sweden.

Substandard and falsified medical products are a public health threat, primarily associated with low- and middle-income countries. Today, the phenomenon also exists in high-income countries. Increased Internet access has opened a global market. Self-diagnosis and self-prescription have boosted the market for unregulated websites with access to falsified medicines.

Biosimilar Agents for Psoriasis Treatment: The Perspective of Portuguese Patients.

Biosimilars are highly similar copies of previously approved original biologic medicines. Their introduction on the market may yield cost reduction. The aim of this study was to evaluate the perspectives of psoriasis patients on biosimilar medications.

The nocebo effect: a clinical challenge in the era of biosimilars.

The nocebo effect is defined as a negative effect of a pharmacological or non-pharmacological medical treatment that is induced by patients' expectations, and that is unrelated to the physiological action of the treatment. The nocebo effect is an important clinical challenge in the current era of biosimilars. Areas covered: This review aims to answer five key questions about the nocebo effect, namely to reveal its definition, pathophysiology, clinical relevance, contributing factors, and management. Expert ...


Advertisement
Quick Search
Advertisement
Advertisement